InVentiv adds Veeva's study start-up tool to eClinical suite

data

InVentiv Health has started using Veeva Systems’ ($VEEV) study start-up application to accelerate trial site activation. The deal builds on inVentiv’s use of Veeva Vault eTMF and, as such, provides a blueprint for how the software player can make inroads into eClinical by upselling to existing customers.

Veeva introduced its study start-up application late last year to provide clinical research teams with a way to collate and manage all of the documents and resources that go into getting a trial off the ground. For CROs such as inVentiv, part of the appeal lies in the ability to share information with sponsors and sites. When paired to automated global workflows and metrics showing the progress toward country and site activation, the pitch was strong enough to persuade inVentiv to start using the application.

“We recognized the value an innovative technology solution could have in knocking down hurdles that slow progress during the study start-up phase, where improvements can have a significant impact on overall trial results,” inVentiv CIO Rachel Stahler said in a statement. “InVentiv identified Veeva as a best-of-breed platform that can maximize efficiencies and accelerate the delivery of much needed drugs to patients.”

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

Veeva has built the study start-up application to dovetail with its eTMF offering, which inVentiv already uses to manage the electronic trial master files generated in the trials it oversees. InVentiv signed up to use Veeva Vault eTMF two years ago. And, with that deal partly tying inVentiv to Veeva’s software suite, it has decided it is best served by turning to the same company to meet its study start-up needs.

The pathway taken by inVentiv provides a blueprint for how Veeva can gain ground in eClinical. While Veeva will be hardpressed to get companies to embrace its whole suite from day one, it does stand a chance of signing them up to a single product and then pushing to expand the deals. This mirrors the approach taken by Medidata ($MDSO), which used its Rave EDC system as a beachhead for growth of its other products.

With Veeva set to introduce its own EDC system, the same strategy could now provide a threat to Medidata’s dominance of its core market.

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.